Letermovir Noninferior for CMV Prophylaxis in Kidney Recipients
TUESDAY, June 13, 2023 -- Letermovir is noninferior to valganciclovir for prevention of cytomegalovirus (CMV) among CMV-seronegative kidney transplant recipients who receive an organ from a CMV-seropositive donor, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cytomegalovirus | Kidney Transplant | Kidney Transplantation | Pharmaceuticals | Study | Transplant Surgery | Transplants | Urology & Nephrology